Salute e Benessere

After 40 Years of Wellness, Technogym Launches Healthness™

Over the years, Technogym has built an ecosystem that, as of today, connects 25 million users (out of a gobal community of 70 million people training with Technogym), industry operators, doctors, and trainers worldwide. Leveraging the company's years of investments in cutting-edge technologies and AI, Nerio Alessandri introduced the new vision of Healthness. Over the years, Technogym has built an ecosystem that, as of today, connects 25 million users (out of a gobal community of 70 million...
PR Newswire
20/02/2025

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of…

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20 thCongress of ECCONANTES, France – February 20, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today presented positive preclinical data on the combination of anti-IL-7 receptor (IL-7R) with anti-IL-12/23 monoclonal antibody (mAb) in chronic colitis at the 20 thCongress of ECCO (European...
Nasdaq GlobeNewswire
20/02/2025

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for…

NEW YORK and VIENNA, Austria, Feb.20, 2025(GLOBE NEWSWIRE) --NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014,...
Nasdaq GlobeNewswire
20/02/2025

Trocars Market is expected to generate a revenue of USD 1.19 Billion by 2031…

The demand for sophisticated surgical instruments is escalating as minimally invasive treatments (MIS) become increasingly prevalent. Trocars, crucial for laparoscopic procedures, are vital in guaranteeing accuracy, efficacy, and patient safety. The trocars industry is witnessing substantial progress in design, material innovation, and technological integration, driven by healthcare providers' focus on minimizing post-operative recovery times and improving surgical results. The demand for...
PR Newswire
20/02/2025

Gene Therapy Market to Hit USD 36.55 Billion by 2032 with 19.4% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962 Browse in-depth TOC on "Gene Therapy Market" 660 - Tables 60 - Figures 433 - Pages Based on therapy type, the gene therapy market is segmented into gene silencing therapy, cell replacement therapy, gene augmentation therapy and other therapies. The gene silencing therapy segment accounted for...
PR Newswire
20/02/2025

UroMems Announces Successful Results in First-Ever Female Clinical Feasibility…

One-year results for the first patient will be presented for the first time by Professor Emmanuel Chartier-Kastler, Urology Chair, Sorbonne University and Pitie-Salpetriere Hospital, Paris, during the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Winter Meeting in Palm Springs, Calif., on Feb. 27th. One-year results for the first patient will be presented for the first time by ProfessorEmmanuel Chartier-Kastler, Urology Chair, Sorbonne University and...
PR Newswire
20/02/2025

Corti Collaborates with Wolters Kluwer to Bring UpToDate's Trusted Clinical…

A recent report from Corti and YouGov found that 75 percent of physicians who use AI in their work see value in leveraging AI for clinical decision support.* To deliver on this value, Corti and Wolters Kluwer Health are integrating evidence-based information from UpToDate, starting with a pilot in the Corti Assistant app. By providing evidence-backed answers during and after consultations, this collaboration will aim to enhance each interaction, improve the quality of care, and make AI…
PR Newswire
20/02/2025

Putting Patients First: Why Europe Must Act to Protect Access To Medicines

Generic Health Check Europe 3.0, shows consolidation of critical generic medicines that is 3 times faster than other generic medicines. This concentration is an actual material risk to the security of critical medicines supply in the region.A diversified supply of critical generic medicines from multiple manufacturers is required to ensure that healthcare systems can meet the needs of their patients. The research shows that for most critical generic medicines' supply (e.g. cardiology,...
Nasdaq GlobeNewswire
20/02/2025

T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors

SAN FRANCISCO and BERLIN, Feb.20, 2025(GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced the appointment of Sophie Papa, FRCP, Ph.D., to its Board of Directors.“We are excited to welcome Dr. Papa to our Board of Directors,” stated Thomas M. Soloway, President and Chief Executive Officer. “T-knife is rapidly advancing TK-6302, a Supercharged PRAME targeting...
Nasdaq GlobeNewswire
20/02/2025

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare…

Media ReleaseCOPENHAGEN, Denmark; February 20, 2025 Approval based on results from two Phase 1/2 EPCORE ®clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or refractory (R/R) follicular lymphoma (FL) who had received two or more lines of systemic therapyEPKINLY is the first and only T-cell engaging bispecific antibody administered subcutaneously approved in Japan to treat both R/R FL and R/R large B-cell lymphomas, after two or more...
Nasdaq GlobeNewswire
20/02/2025

Boehringer Ingelheim and partners start clinical development of a…

Ingelheim, Germany, 20 February 2025– Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1and OXB, 1today announce the start of LENTICLAIR TM1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene therapy aiming to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene mutations that are causing the disease. The trial specifically focuses on adults with CF who genetically cannot benefit from cystic fibrosis...
Nasdaq GlobeNewswire
20/02/2025

Syensqo and Emulseo announce strategic partnership for advanced applications in…

Under this agreement, Emulseo will include Syensqo's advanced solution, Galden® PFPE in its Fluo-Oil range of products to provide its customers with an essential component in creating reliable and performant droplet-based microfluidic analyses. Under this agreement, Emulseo will include Syensqo's advanced solution, Galden® PFPE in its Fluo-Oil range of products to provide its customers with an essential component in creating reliable and performant droplet-based microfluidic analyses. ...
PR Newswire
20/02/2025

Telix 2024 Full Year Results: Record Financial Performance and Investment in…

For a full list of operational achievements, please refer to the Telix 2024 Annual Report. For a full list of operational achievements, please refer to the Telix 2024 Annual Report. Commentary Group CEO, Dr. Christian Behrenbruch, commented on the result: "2024 has been an extraordinary year for Telix. We generated strong financial growth while investing for the future. The Precision Medicine business is poised for step-change growth with three commercial product launches...
PR Newswire
20/02/2025

Zealand Pharma convenes its Annual General Meeting 2025

Company Announcement – No. 3 / 2025 Zealand Pharma convenes its Annual General Meeting 2025Notice to convene the Annual General Meeting 2025 of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Thursday, March 27, 2025 at 3:00 pm (CET) The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or...
Nasdaq GlobeNewswire
20/02/2025

Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance…

Fortrea to Sponsor SCRS' Collaborate Forward Working Group, Encouraging Collaboration for More Efficient Clinical Trials Comprising 16 leadingGlobal Impact Partnerorganizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims...
Nasdaq GlobeNewswire
20/02/2025

This Love Your Pet Day, new research from pet health brand Omni reveals the…

"Skin issues, gut problems, and obesity are soaring among pets, yet few effective nutritional solutions exist. Many rely on CO2-intensive ingredients and are bland in flavour. Omni is changing this with a future-proof approach to pet health - without compromising on taste." Dr. Guy Sandelowsky, Omni's co-founder. "Skin issues, gut problems, and obesity are soaring among pets, yet few effective nutritional solutions exist. Many rely on CO2-intensive ingredients and are bland in…
PR Newswire
20/02/2025

ASSAÍ REACHES R$ 80.6 BILLION IN REVENUE AND REDUCES LEVERAGE IN 2024

"In 2024, we surpassed the milestone of 300 stores and celebrated 50 years with outstanding results," says Belmiro Gomes, CEO of Assaí. "We reduced leverage to 3.04x and remain committed to enhancing the customer shopping experience." The company opened 15 new stores, bringing its total to 302 units and strengthening its presence in strategic markets. Additionally, it completed the conversion of the 66 hypermarkets acquired in 2021. Another major achievement was leverage…
PR Newswire
20/02/2025

Oncoinvent ASA: Invitation to Result Presentation Q4 2024

10.00 CETLive streamed of quarterly presentation in English. A webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar. 10.00 CET Live streamed of quarterly presentation in English. A webcast will be available for everyone to view onwww.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel...
PR Newswire
20/02/2025

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024

Company announcement – No. 2 / 2025Correction includes 2024 Annual Report attached in iXBRL format. Zealand Pharma Announces Financial Results for the Full Year 2024A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the foundation for accelerated growth in the years to comePositive results with long-acting amylin analog petrelintide in 16-week Phase 1b trial and advancement into large, comprehensive Phase 2b...
Nasdaq GlobeNewswire
20/02/2025

EMA validates indication extension application for Aspaveli® for treatment of…

The submission includes positive data from the Phase 3 VALIANT study. The study met its primary endpoint demonstrating a statistically significant and clinically meaningful 68% (p<0.0001) proteinuria reduction in pegcetacoplan-treated patients compared to placebo. At week 26, results were consistent agross subgroups, including disease type, age, and transplant status. The submission includes positive data from the Phase 3 VALIANT study. The study met its primary endpoint demonstrating a...
PR Newswire
20/02/2025

Hotel & Shop Plus 2025 Preview: Exploring Symbiotic Innovation in the Hotel…

2025 Speaker Lineup Released: 2025 Speaker Lineup Released: At Hotel & Shop Plus, top exhibitors will showcase innovative products and solutions. For example, ARROW will provide high - quality intelligent sanitary solutions for hotel clients. Its new products, such as the X7 smart toilet and the YURI urinal, demonstrate the perfect blend of technology and quality, heralding a new era of smart bathroom solutions. Exhibitors in the building materials category, including Jomoo, Simon,...
PR Newswire
20/02/2025

EG 427 raises €27 million in successful Series B co-led by Andera Partners and…

Specialist fund SCI Ventures, backed by major spinal cord injury foundations, together with existing investors, also participated in this roundProceeds will finance phase 1b/2a study of EG110A through safety and early efficacy results Opens way for clinical development across multiple medically important neuro-urology pathologiesFunding will also support the company's early-stage pipeline based on its proprietary HERMES vector technology platform.Paris, France, February 20, 2025–...
Nasdaq GlobeNewswire
20/02/2025

Mars launches landmark global study program on pets' contribution to human…

Loïc Moutault, President of Mars Petcare, said: "As a pet owner, I know firsthand the joy and comfort pets bring to our lives and there is increasing evidence that owning a pet or simply interacting with one can bring benefits to people of all ages and from all walks of life. We're aiming to deliver on our Purpose: A Better World for Pets, because we believe pets make our lives better, and through this study program we aim to provide deeper, science-backed understanding of the mutual bond…
PR Newswire
20/02/2025

Fagron delivers exceptional performance with 14% topline growth and 17% increase…

Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 February 2025 – 7AM CET Fagron delivers exceptional performance with 14% topline growth and 17% increase in REBITDA for FY 2024 Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2024.Key Highlights Exceptional topline performance with 14.3% reported growth (15.9% at CER) and 13.0% organic growth at...
Nasdaq GlobeNewswire
20/02/2025
Altri  Comunicati